Johnson & Johnson Hits New 52-Week High at USD 251.59

Johnson & Johnson has reached a significant milestone by hitting a new 52-week high of USD 251.59 on March 2, 2026. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it holds a substantial market capitalization of USD 702,556 million, categorizing it as a large-cap stock. Over the past year, Johnson & Johnson has demonstrated impressive growth, with a performance increase of 68.94%, significantly outpacing the S&P 500's 17.36% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 28.00, reflecting its valuation in the market. Additionally, Johnson & Johnson maintains a healthy dividend yield of 1.44%, appealing to income-focused investors. The company's financial metrics further highlight its robust position, with a return on equity of 27.89% and a debt-to-equity ratio of 0.34, indicating effective management of its capital structure. The stock's previous 52-week low was recorded at USD 141.50, marking a significant upward trajectory in its valuation.